Although the patho-physiologic implications of the S100 proteins in cancer still require further clarification, the description of their differential occurrence in a large group of breast cancer patients, at proteomic levels, is a further important step promoting advancement of scientific knowledge for biomarker application in clinical practice. This evidence concerns the gene S100A1 and breast cancer.